This investment from the Pacific Economic Development Agency of Canada will help broaden the application of Aspect’s bioprinting technology for therapeutic development, expand its global network of partners, and scale-up its manufacturing systems
Vancouver, BC, Canada - March 20, 2023 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, announced today that it has received over $3.6 million in funding from the Government of Canada.
The federal funding announcement was made at Aspect Biosystems in Vancouver by the Honourable Harjit S. Sajjan, Minister of International Development and Minister responsible for the Pacific Economic Development Agency of Canada (PacifiCan). The funding was awarded through PacifiCan’s Business Scale-Up and Productivity (BSP) program.
This investment will help Aspect Biosystems broaden the application of its bioprinting technology, expand its global network of partners, and scale-up its manufacturing systems to increase productivity and the potential for its platform to create the next generation of life-changing therapies.
“Canada has a rich history in regenerative medicine, and we are proud to be pioneering the next frontier of advanced living therapies from here in British Columbia,” said Tamer Mohamed, Chief Executive Officer, Aspect Biosystems. “This support from the Government of Canada will help further our mission of developing bioprinted tissue therapeutics to transform how we treat disease.”
“Creating opportunities for B.C. based businesses to thrive is a key priority for PacifiCan,” said the Honourable Harjit S. Sajjan, Minister of International Development and Minister responsible for the Pacific Economic Development Agency of Canada. “This funding will enhance the competitiveness of Canada’s life sciences sector, supporting strong economic growth and enabling critical advances in healthcare.”
Read the Government of Canada press release here.
About the Pacific Economic Development Agency of Canada (PacifiCan)
PacifiCan is the federal economic development agency dedicated to British Columbians. PacifiCan works with partners who are building innovative businesses, creating quality jobs, and supporting inclusive growth throughout our province. PacifiCan’s Business Scale-up and Productivity (BSP) program makes strategic investments in key economic sectors, helping innovative companies accelerate their growth and compete globally.
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases. Learn more at www.aspectbiosystems.com.
Contact
Natalie Korenic
Aspect Biosystems
+1-604-263-0502
media@aspectbiosystems.com